Frontlight ResearchEarly access
Taking people in SpainPhase 1
Tests daraxonrasib with pembrolizumab in lung cancer with RAS mutations
Tests whether daraxonrasib with pembrolizumab is safe in adults with advanced RAS-mutated lung cancer.
Key facts
- Who runs it
- Revolution Medicines Inc.
- Where
- A Coruña, Badalona, Barcelona, Madrid, Málaga, Pamplona, Sevilla, and Valencia, SpainSee the 13 sitesAlso in 4 other countries, 28 sites
- Trial code
- EU 2023-509572-42-00
- NCT06162221
- Registry title
- A study of Daraxonrasib (RMC-6236) in combination with pembrolizumab in participants with nonsmall cell lung cancer with certain mutations -Subprotocol B
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 180 people, planned
- Started
- 17 Jul 2024
- Expected to end
- 7 Oct 2027
- Type of study
- Interventional
- Record updated
- 22 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced non-small cell lung cancer (NSCLC) that has certain RAS mutations. They get daraxonrasib with pembrolizumab, with or without chemotherapy.
- Age
- 18 years or older, or the legal age of consent.
- Sex
- Men and women can join.
- Disease stage
- NSCLC with certain RAS mutations that is unlikely to be cured and has grown or spread to other body parts. At least one tumor lesion that can be measured.
- Earlier treatment
- People who have had prior cancer treatment, are not fit for standard treatments, or have no standard treatment available. Prior targeted therapy for a RAS mutation is not allowed.
- Biomarker or test result
- Certain RAS mutations in the lung cancer.
Main reasons for not taking part
- Primary brain or spinal cord tumor spreading to other body parts
- Stomach or bowel problems that may affect how daraxonrasib is absorbed
- Major surgery in the last 4 weeks
- Earlier targeted therapy for a RAS mutation
- Other medical conditions, medicines or foods that may interfere with the study drugs
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Patients that are at least 18 years old or legal age of consent Patients that have NSCLC with certain RAS mutations. Patients that have NSCLC that is unlikely to be cured and has grown or spread to other body parts. Patients that have received prior cancer treatment, are not suitable for standard treatments, or no standard treatments are available.. Patients that have at least one tumor lesion (an area of abnormal tissue) that can be measured. Patients that have adequate organ function (bone marrow, liver, kidney)
Who cannot take part
- Participants that have primary brain and spinal cord tumor spreading to other body parts. 2. Participants that have gastrointestinal problems that may affect absorption of daraxonrasib. 3. Participants that had any major surgery in the last 4 weeks. 4. Participants that have have previously taken targeted therapy for RAS mutation. 5. Participants that have any other medical condition that may interfere with the study drugs. 6. Participants that need other medicines, treatments or eating foods that may interfere with study drugs
Where in Spain
Also in 4 other countries, 28 sites
- Complexo Hospitalario Universitario A CoruñaA Coruña, SpainTaking people
- Institut Catala d'OncologiaBadalona, SpainTaking people
- Hospital Universitari Vall d'HebronBarcelona, SpainTaking people
- Clinica Universidad de NavarraMadrid, SpainTaking people
- Hospital Clínico San CarlosMadrid, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- Hospital Universitario Fundación Jiménez DíazMadrid, SpainTaking people
- Hospital Universitario Ramón y CajalMadrid, SpainTaking people
- Hospital Universitario Regional de MálagaMálaga, SpainTaking people
- Clínica Universidad de navarraPamplona, SpainTaking people
- University Hospital Virgen Del Rocio S.L.Sevilla, SpainTaking people
- Fundación Instituto Valenciano de OncologíaValencia, SpainTaking people
- Hospital Universitario Y Politecnico La FeValencia, SpainTaking people
About the trial
What the trial wants to find out
To evaluate the safety and tolerability of daraxonrasib in combination with pembrolizumab, with or without chemotherapy, in patients with advanced RAS- mutated NSCLC
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 1b/2 Open-Label, Multicenter Study of Daraxonrasib (RMC-6236) in Combination with Pembrolizumab with or without Chemotherapy, in Patients with RAS‑Mutated Non-Small Cell Lung Cancer (NSCLC) – Subprotocol B
- Plain-language title
- Tests daraxonrasib with pembrolizumab in lung cancer with RAS mutationsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 11 November 2026.
- Record updated
- 22 September 2026